169 results
Page 5 of 9
8-K
EX-99.1
gcg6y
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
8-K
EX-99.1
fvlyiax17g
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am
8-K
EX-99.1
rm6bw3 o49uex
7 Feb 20
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
4:20pm
424B5
e8ay vqttv02lb6i
22 Jan 20
Prospectus supplement for primary offering
5:31pm
8-K
EX-99.2
liwpjwjsjb0n
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-99.1
3vm1rv
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-1.1
qjrleq3a4n goqi6frmx
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
424B5
hyw61xs0 mdozuv3o173
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
t22xeab39 d68dwn
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
EX-99.1
wl6c7v3b beh3gjhx8
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-99.1
57qj v3kc6t
13 Jan 20
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
7:09am
8-K
EX-99.1
cb5lk
6 Nov 19
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
7:35am
8-K
EX-99.1
kjwftx48xd6zg0fh2r6
1 Oct 19
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
8:14am
8-K
EX-99.1
hf9w9e1
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am